BTG Seeks Exclusive Licensee for a Fundamental Technology on Transparent Cathodes in Polymer OLED Devices.WEST CONSHOHOCKEN, Pa. -- BTG BTG BIT (Built-In Test) Target Generator BTG Bridging the Gap BTG British Technology Group BtG Betreuungsgesetz (Germany) BTG Biomass Technology Group BV BTG Begbies Traynor Group (LSE LSE - Language Sensitive Editor : BGC BGC General Cable Corporation (stock symbol) BGC Billy Graham Center BGC Baptist General Conference (formerly Swedish Baptist Denomination) BGC Boys & Girls Club BGC Bubblegum Crisis ), the intellectual property and technology commercialization company, today announced its plan to seek an exclusive licensee for a fundamental technology that uses transparent cathodes in polymer organic light emitting diode See LED. (OLED (Organic Light Emitting Device, Organic Light Emitting Diode) A thin film light-emitting technology that is expected to compete with LCD and plasma TVs as well as LCD monitors and readouts. ) devices. This fundamental technology includes US Patent 5,955,834 titled Light Emitting Devices Utilizing High Work Function Electrodes, and is one of a comprehensive portfolio of granted US patents and published applications licensed by BTG from The Ohio State University Ohio State University, main campus at Columbus; land-grant and state supported; coeducational; chartered 1870, opened 1873 as Ohio Agricultural and Mechanical College, renamed 1878. There are also campuses at Lima, Mansfield, Marion, and Newark. covering OLED technologies in the field of information displays. BTG has established a dedicated team of OLED scientists to work on the commercial development of the patent portfolio in the state-of-the-art clean room facility and chemistry laboratory at the Ohio MicroMD Laboratory on the campus of The Ohio State University in Columbus, Ohio. Working with the development team are commercialization and patent executives in BTG's European and North American offices to build upon the existing patent portfolio and its exploitation. Professor Arthur Epstein, Distinguished University Professor, Department of Physics and Chemistry, and principal inventor of the technology at The Ohio State University, continues to support the development activities through a consultancy role to BTG. BTG has invested a significant amount of its own development funding to demonstrate the technology for future polymer OLED product applications, to protect the intellectual property, and to commercialize the portfolio of patents, applications, prototypes, and know-how. BTG now seeks to exclusively license this technology to one OLED manufacturing company, thereby giving them a competitive position in growing markets for polymer OLED products. Growing OLED markets enabled by this technology will use active matrix (AM) displays requiring transparent cathodes in either top emission or bottom emission (inverted inverted reverse in position, direction or order. inverted L block a pattern of local filtration anesthesia commonly used in laparotomy in the ox. ) structures. The size of the AM displays can range from micro-displays, such as video camera viewfinders, to large sizes, such as polymer OLED televisions, which have recently been demonstrated through prototypes at various technology conferences in North America and Asia. About BTG BTG is an intellectual property and technology commercialization company that operates internationally. BTG creates value by investing in intellectual property and technology development, and in early stage ventures. We realize value through technology licensing, patent assertion and sale of equity investments. Through a multidisciplinary approach, we apply intellectual property and commercial expertise, together with specialist skills in science and technology, to create major product opportunities in the health and high tech sectors. BTG has commercialized important innovations, including Magnetic Resonance Imaging magnetic resonance imaging (MRI), noninvasive diagnostic technique that uses nuclear magnetic resonance to produce cross-sectional images of organs and other internal body structures. , Multilevel Cell Memory, Campath(R) (alemtuzumab), the first monoclonal antibody treatment for chronic lymphocytic leukemia chronic lymphocytic leukemia n. Abbr. CLL Lymphocytic leukemia occurring mainly in older adults, characterized by slow onset and gradual progression of symptoms. , and recombinant Factor IX blood clotting protein. BTG operates through wholly owned subsidiaries BTG International Ltd. and BTG International Inc. in the UK and USA, respectively. OLED companies interested in entering into negotiations with BTG should contact: |
|
||||||||||||||

Printer friendly
Cite/link
Email
Feedback
Reader Opinion